Glioma Clinical Trials in Dallas, Texas

4 studies are recruiting for glioma in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

   This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Locations

   61 in total

   Run by

   Nuvation Bio Inc.

   See if you can join NCT05303519 on ClinicalTrials.gov

2. A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

   This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment opti…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology - Dallas, Dallas, Texas

   Locations

   23 in total

   Run by

   Nested Therapeutics, Inc

   See if you can join NCT06326411 on ClinicalTrials.gov

3. ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

   This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline radiotherapy will extend overall survival and progression-fr…

   Stage

   Phase 3

   Ages

   Any age

   Site

   Neuro-Oncology Associates, Dallas, Texas

   Locations

   162 in total

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT05580562 on ClinicalTrials.gov

4. Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

   This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy tr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UT Southwestern Medical Center, Dallas, Texas

   Locations

   3 in total

   Run by

   Cerenome

   See if you can join NCT01906385 on ClinicalTrials.gov